VO659
Asset
Antisense oligonucleotide targeting expanded CAG-repeat RNA to reduce production of toxic polyglutamine proteins.
- Stage
- Phase 2
- Modality
- Oligonucleotide
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
13 and Huntington's disease spinocerebellar ataxia types 1
Phase 2, Not yet recruiting, CTIS2026-526408-60-00, euclinicaltrials.eu, Oct 28, 2026
In the full profile
- Owner and partners1
- Trials1
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.